(Q48334436)

English

Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer.

scientific article published on 23 January 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/20099049

Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer. (English)

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/20099049

immunohistochemistry

1 reference

based on heuristic

inferred from title

Kadri Altundağ

5

object named as

Kadri Altundag

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/20099049

author name string

Ebru Sari

1

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/20099049

Gulnur Guler

2

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/20099049

Mutlu Hayran

3

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/20099049

Ibrahim Gullu

4

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/20099049

Yavuz Ozisik

6

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/20099049

publication date

23 January 2010

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/20099049

Medical Oncology

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/20099049

28

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/20099049

1

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/20099049

57-63

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/20099049

https://scigraph.springernature.com/pub.10.1007/s12032-010-9418-2

0 references

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9418-2

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9418-2

21 January 2018

Genetic alterations in breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9418-2

21 January 2018

Cytogenetic polyclonality in tumors of the breast.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9418-2

21 January 2018

Variation in receptor status between primary and metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9418-2

21 January 2018

Impact of metastatic estrogen receptor and progesterone receptor status on survival

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9418-2

21 January 2018

Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9418-2

21 January 2018

Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9418-2

21 January 2018

Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9418-2

21 January 2018

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9418-2

21 January 2018

HER2 gene status in primary breast cancers and matched distant metastases

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9418-2

21 January 2018

HER-2/neu expression in primary and metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9418-2

21 January 2018

Current issues in ER and HER2 testing by IHC in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9418-2

21 January 2018

The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9418-2

21 January 2018

Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9418-2

21 January 2018

Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9418-2

21 January 2018

Discordance between receptor status in primary and metastatic breast cancer: an exploratory study of bone and bone marrow biopsies

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9418-2

21 January 2018

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20099049

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20099049

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estrogen and progesterone receptor concordance between primary and recurrent breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20099049

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Marked Intratumoral Heterogeneity of the Proto-Oncogene Her-2/neu Determined by Three Different Detection Systems

1 reference

https://pubmed.ncbi.nlm.nih.gov/20099049

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

erbB-2 (HER-2) and breast cancer progression.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20099049

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites

1 reference

https://pubmed.ncbi.nlm.nih.gov/20099049

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequential estrogen receptor determinations from primary breast cancer and at relapse: prognostic and therapeutic relevance. The International Breast Cancer Study Group (formerly Ludwig Group)

1 reference

https://pubmed.ncbi.nlm.nih.gov/20099049

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20099049

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20099049

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20099049

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20099049

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clonal heterogeneity in breast cancer: Karyotypic comparisons of multiple intra—and extra—tumorous samples from 3 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20099049

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20099049

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20099049

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12032-010-9418-2

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/20099049

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/20099049

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48334436&oldid=1404967371"